Abstract
Objective: HIV is a cardiovascular disease (CVD) risk factor. However, CVD risk is often underestimated in HIV-infected women. C-reactive protein (CRP) may improve CVD prediction in this population. We examined the association of baseline plasma CRP with subclinical CVD in women with and without HIV. Design: Retrospective cohort study. Methods: A total of 572 HIV-infected and 211 HIV-uninfected women enrolled in the Women's Interagency HIV Study underwent serial high-resolution B-mode carotid artery ultrasonography between 2004 and 2013 to assess carotid intima-media thickness (CIMT) and focal carotid artery plaques. We used multivariable linear and logistic regression models to assess the association of baseline high (≥3 mg/l) high-sensitivity (hs) CRP with baseline CIMT and focal plaques, and used multivariable linear and Poisson regression models for the associations of high hsCRP with CIMT change and focal plaque progression. We stratified our analyses by HIV status. Results: Median (interquartile range) hsCRP was 2.2 mg/l (0.8-5.3) in HIV-infected, and 3.2 mg/l (0.9-7.7) in HIV-uninfected, women (P = 0.005). There was no statistically significant association of hsCRP with baseline CIMT [adjusted mean difference -3.5 μm (95% confidence interval:-19.0 to 12.1)] or focal plaques [adjusted odds ratio: 1.31 (0.67-2.67)], and no statistically significant association of hsCRP with CIMT change [adjusted mean difference 11.4 μm (-2.3 to 25.1)]. However, hsCRP at least 3 mg/l was positively associated with focal plaque progression in HIV-uninfected [adjusted rate ratio: 5.97 (1.46-24.43)], but not in HIV-infected [adjusted rate ratio: 0.81 (0.47-1.42)] women (P = 0.042 for interaction). Conclusion: In our cohort of women with similar CVD risk factors, higher baseline hsCRP is positively associated with carotid plaque progression in HIV-uninfected, but not HIV-infected, women, suggesting that subclinical CVD pathogenesis may be different HIV-infected women.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 999-1006 |
| Number of pages | 8 |
| Journal | AIDS |
| Volume | 32 |
| Issue number | 8 |
| DOIs | |
| State | Published - May 15 2018 |
Fingerprint
Keywords
- atherosclerosis
- C-reactive protein
- HIV
- subclinical cardiovascular disease
- women
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Infectious Diseases
Cite this
The association of C-reactive protein with subclinical cardiovascular disease in HIV-infected and HIV-uninfected women. / Moran, Caitlin A.; Sheth, Anandi N.; Mehta, C. Christina; Hanna, David B.; Gustafson, Deborah R.; Plankey, Michael W.; Mack, Wendy J.; Tien, Phyllis C.; French, Audrey L.; Golub, Elizabeth T.; Quyyumi, Arshed; Kaplan, Robert C.; Ofotokun, Ighovwerha.
In: AIDS, Vol. 32, No. 8, 15.05.2018, p. 999-1006.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The association of C-reactive protein with subclinical cardiovascular disease in HIV-infected and HIV-uninfected women
AU - Moran, Caitlin A.
AU - Sheth, Anandi N.
AU - Mehta, C. Christina
AU - Hanna, David B.
AU - Gustafson, Deborah R.
AU - Plankey, Michael W.
AU - Mack, Wendy J.
AU - Tien, Phyllis C.
AU - French, Audrey L.
AU - Golub, Elizabeth T.
AU - Quyyumi, Arshed
AU - Kaplan, Robert C.
AU - Ofotokun, Ighovwerha
PY - 2018/5/15
Y1 - 2018/5/15
N2 - Objective: HIV is a cardiovascular disease (CVD) risk factor. However, CVD risk is often underestimated in HIV-infected women. C-reactive protein (CRP) may improve CVD prediction in this population. We examined the association of baseline plasma CRP with subclinical CVD in women with and without HIV. Design: Retrospective cohort study. Methods: A total of 572 HIV-infected and 211 HIV-uninfected women enrolled in the Women's Interagency HIV Study underwent serial high-resolution B-mode carotid artery ultrasonography between 2004 and 2013 to assess carotid intima-media thickness (CIMT) and focal carotid artery plaques. We used multivariable linear and logistic regression models to assess the association of baseline high (≥3 mg/l) high-sensitivity (hs) CRP with baseline CIMT and focal plaques, and used multivariable linear and Poisson regression models for the associations of high hsCRP with CIMT change and focal plaque progression. We stratified our analyses by HIV status. Results: Median (interquartile range) hsCRP was 2.2 mg/l (0.8-5.3) in HIV-infected, and 3.2 mg/l (0.9-7.7) in HIV-uninfected, women (P = 0.005). There was no statistically significant association of hsCRP with baseline CIMT [adjusted mean difference -3.5 μm (95% confidence interval:-19.0 to 12.1)] or focal plaques [adjusted odds ratio: 1.31 (0.67-2.67)], and no statistically significant association of hsCRP with CIMT change [adjusted mean difference 11.4 μm (-2.3 to 25.1)]. However, hsCRP at least 3 mg/l was positively associated with focal plaque progression in HIV-uninfected [adjusted rate ratio: 5.97 (1.46-24.43)], but not in HIV-infected [adjusted rate ratio: 0.81 (0.47-1.42)] women (P = 0.042 for interaction). Conclusion: In our cohort of women with similar CVD risk factors, higher baseline hsCRP is positively associated with carotid plaque progression in HIV-uninfected, but not HIV-infected, women, suggesting that subclinical CVD pathogenesis may be different HIV-infected women.
AB - Objective: HIV is a cardiovascular disease (CVD) risk factor. However, CVD risk is often underestimated in HIV-infected women. C-reactive protein (CRP) may improve CVD prediction in this population. We examined the association of baseline plasma CRP with subclinical CVD in women with and without HIV. Design: Retrospective cohort study. Methods: A total of 572 HIV-infected and 211 HIV-uninfected women enrolled in the Women's Interagency HIV Study underwent serial high-resolution B-mode carotid artery ultrasonography between 2004 and 2013 to assess carotid intima-media thickness (CIMT) and focal carotid artery plaques. We used multivariable linear and logistic regression models to assess the association of baseline high (≥3 mg/l) high-sensitivity (hs) CRP with baseline CIMT and focal plaques, and used multivariable linear and Poisson regression models for the associations of high hsCRP with CIMT change and focal plaque progression. We stratified our analyses by HIV status. Results: Median (interquartile range) hsCRP was 2.2 mg/l (0.8-5.3) in HIV-infected, and 3.2 mg/l (0.9-7.7) in HIV-uninfected, women (P = 0.005). There was no statistically significant association of hsCRP with baseline CIMT [adjusted mean difference -3.5 μm (95% confidence interval:-19.0 to 12.1)] or focal plaques [adjusted odds ratio: 1.31 (0.67-2.67)], and no statistically significant association of hsCRP with CIMT change [adjusted mean difference 11.4 μm (-2.3 to 25.1)]. However, hsCRP at least 3 mg/l was positively associated with focal plaque progression in HIV-uninfected [adjusted rate ratio: 5.97 (1.46-24.43)], but not in HIV-infected [adjusted rate ratio: 0.81 (0.47-1.42)] women (P = 0.042 for interaction). Conclusion: In our cohort of women with similar CVD risk factors, higher baseline hsCRP is positively associated with carotid plaque progression in HIV-uninfected, but not HIV-infected, women, suggesting that subclinical CVD pathogenesis may be different HIV-infected women.
KW - atherosclerosis
KW - C-reactive protein
KW - HIV
KW - subclinical cardiovascular disease
KW - women
UR - http://www.scopus.com/inward/record.url?scp=85046718826&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046718826&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000001785
DO - 10.1097/QAD.0000000000001785
M3 - Article
C2 - 29438198
AN - SCOPUS:85046718826
VL - 32
SP - 999
EP - 1006
JO - AIDS
JF - AIDS
SN - 0269-9370
IS - 8
ER -